Background: Suppression of the SOS response has been proposed as a therapeutic strategy for potentiating quinolones against susceptible, low-level quinolone-resistant (LLQR) and resistant Enterobacteriaceae.
Introduction
Most efforts in the fight against antimicrobial resistance have focused on modifying existing antibiotics by circumventing the molecular mechanisms that confer resistance. 1 However, new strategies are needed to block and reverse the development of clinical resistance and extend the life of antibiotics. Antibiotic therapy can facilitate adaptive resistance mutations and the acquisition of resistance genes by promoting the activation of RecA (initiating the SOS response involving the DNA repair and mutagenesis pathways). [2] [3] [4] Fluoroquinolones are potent inducers of the SOS response at both lethal and sub-lethal concentrations, causing DNA damage or arresting replication forks by blocking type II topoisomerases. 2, 4, 5 The SOS response is induced after RecA activation, which triggers self-cleavage of the LexA repressor. 2, 4 Moreover, RecA is a multifunctional protein involved in DNA repair, recombination, induction of the SOS response, horizontal gene transfer, motility and biofilm formation. 4, [6] [7] [8] V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Enterobacteriaceae such as Escherichia coli are among the most common causes of community-acquired and nosocomial infections. Fluoroquinolones are used for empirical and directed therapy in infections caused by E. coli. 9 Quinolone resistance in both human and veterinary isolates of Enterobacteriaceae has increased notably. 10, 11 The mechanisms of fluoroquinolone resistance mainly involve chromosomal mutations in genes encoding quinolone targets (type II topoisomerases), but also involve reduced permeability. 11 Plasmid-mediated quinolone resistance mechanisms are also epidemiologically relevant. 12 These determinants on their own confer low-level quinolone resistance (LLQR), and therefore multiple mechanisms must be combined to achieve clinical resistance. 12 Suppression of the SOS response was recently revealed as a therapeutic strategy for potentiating bactericidal antibiotics such as quinolones against both susceptible and resistant E. coli, leading to their resensitization to drugs such as quinolones. 13, 14 Several compounds have been validated for the inhibition of RecA activity in vitro and in vivo, leading to increased antimicrobial activity. 15, 16 Although targeting the SOS response seems a promising strategy for developing therapeutics to enhance the bactericidal activity of antimicrobial agents, significant questions remain unanswered regarding the possible impact of this approach as an evolutionary strategy for reversing and tackling the evolution of antibiotic resistance. 17, 18 To address this question, we used a collection of isogenic E. coli mutants (Table S1, 14 available as Supplementary data at JAC Online) exhibiting a spectrum of SOS activity, from a natural SOS response to hypoinducible (LexA1, with very low cleavage rate) 19 and constitutively suppressed responses (DrecA), also carrying combinations of chromosomally and plasmid-mediated quinolone resistance (PMQR) mechanisms (including susceptible, LLQR and resistant phenotypes). The impact of suppression of the SOS response on the spatiotemporal evolution of resistance and other relevant biological parameters, such as bacterial fitness, biofilm formation and post-antibiotic effects (PAEs), under therapeutic concentrations was investigated.
Materials and methods

Strains, growth conditions and antimicrobial agents
Sixteen isogenic E. coli strains were used (based on WT E. coli ATCC 25922) harbouring chromosomally mediated and/or plasmid-mediated quinolone resistance mechanisms combined with recA deletion and/or lexA replacement by lexA1
14 (see Table S1 ).
Liquid or solid LB medium and Mueller-Hinton broth (MHB) were used. Strains were grown at 37 C. Ciprofloxacin was used for the different assays (Sigma-Aldrich, Madrid, Spain). Kanamycin (Sigma-Aldrich, Madrid, Spain) at 30 mg/L was used for plasmid maintenance. The qnrS gene was cloned into the pBK-CMV vector as described previously. 20 Expression of ciprofloxacin-induced GFP in the kanamycin-resistant pMSrecA-gfp vector was used to detect recA promoter activity (SOS induction). 21 
Determination of mutation rate
Overnight cultures of E. coli were diluted 1:10000 and incubated for 16 h in the absence of ciprofloxacin. The mutation rate was determined by spreading an overnight culture of viable microorganisms (100 lL) from 5 mL cultures on LB agar plates, with and without ciprofloxacin (with 4%MIC as the selective concentration). Ciprofloxacin concentrations were relative to MICs for strains harbouring the unmodified SOS response (i.e. with intact recA and lexA genes). Selected isogenic groups were also exposed to fixed selective concentrations of ciprofloxacin: 1 mg/L for the ATCC, EC02 and EC04 groups (CLSI breakpoint for resistance) 22 and 2.5 mg/L for the EC04, EC08 and EC09 groups [peak serum ciprofloxacin concentrations (C max )]. 23 These concentrations allow selection of different types of mutants. The colony count was determined after 48 h at 37 C in three independent assays. The colony counts from the three replicates were then used in the MSS maximum-likelihood method using the FALCOR web site (http://www.mito chondria.org/protocols/FALCOR.html) 24 to estimate the number of mutational events per culture.
Mutant prevention concentration (MPC) determination
MPCs were determined as previously described by Marcusson et al. 25 The MPC was recorded as the lowest quinolone concentration at which no colonies grew on an agar plate. The MPC for each strain was determined in at least two independent experiments.
Agar gradient plate experiments
A key aspect of bacterial survival is the ability to evolve while migrating across spatially varying environmental challenges. 26 Gradient plate assays (120.5 mm) were used to evaluate microbial evolution as a function of the SOS response available. Several maximum concentrations of ciprofloxacin were used: 1 and 2.5 mg/L, and 1% or 4%MIC (relative to the WT SOS response). BM2 swarming medium was used 27 (see Supplementary Methods). The plates were incubated for a maximum of 240 h. 28 
Whole genome sequencing
Genomic DNA from 29 evolved mutants (obtained from the zone separating growth and non-growth) and their respective parental strains was extracted and sequenced using MiSeq (Illumina, San Diego, CA, USA). Raw reads were quality filtered and assembled into contigs using the CLC genomics workbench 9.5.2. (CLC bio, QIAGEN) and analysed (see Supplementary Methods).
Growth competition assays
E. coli ATCC 25922, EC02, EC04, EC08 and EC09 were used as standard reference strains against derived DrecA (kanamycin-resistant) mutants. EC59 DlacZ was tested against EC59 DrecA (DlacZ mutation is neutral). 20 Fitness cost was determined as previously described by Marcusson et al. 25 (see Supplementary Methods). A relative fitness (RF) score .1 indicated that the mutant strain had a selective advantage over the control strain, whereas a score ,1 represented a fitness cost. Competition assays were also carried out at 0.5%MIC of ciprofloxacin. Ciprofloxacin concentrations were relative to MICs for strains harbouring the modified SOS response (recA deleted). The ATCC, EC02 and EC04 groups were also exposed to environmental concentrations of ciprofloxacin (0.002 mg/L). 29 Each competition assay was tested in at least six independent experiments.
Determination of the PAE of ciprofloxacin ATCC, EC02, EC04 and EC08 groups were selected to show the impact of suppression of the SOS response on the PAE in vitro by exposing the bacteria (10 7 cfu/mL) to fixed concentrations of 1 and 2.5 mg/L of ciprofloxacin for 2 h. The antibiotic was removed from the culture by three centrifugations, and the bacteria were resuspended in fresh MHB. The antibiotic-free bacterial suspension was then incubated at 37 C and shaken. After removal of the drug, viable counts were performed hourly for the next 6 h and at 24 h. A growth control, prepared and treated in a similar way to the test solution but without being exposed to antibiotics, was included in each experiment. The PAE was calculated as previously described. 30 Blocking quinolone resistance by suppressing the SOS response
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Biofilm production
Biofilm production was assessed by a previously described spectrophotometric method 31 (see Supplementary Methods). Sub-MIC concentrations of ciprofloxacin (1/16%MIC for each of the respective SOS WT strains) were evaluated.
Statistical analysis
For statistical evaluation, Student's t-test was used when two groups were compared. Differences were considered significant when P values were 0.05.
Results
Suppression of the SOS response reduces emergence of mutants in LLQR E. coli
Five isogenic E. coli strains were used that harbour the most frequent chromosomal mutations associated with fluoroquinolone resistance in the gyrA and/or parC genes and/or a deletion in the marR gene combined with the PMQR mechanism (qnrS) (ranging from WT high susceptibility to a high level of resistance). In order to evaluate the impact of the SOS response on the emergence of mutants in LLQR E. coli, the SOS response was suppressed in all strains by means of recA deletion or replacement of lexA by lexA1 (Table S1 ). MICs were in the range 0.004-4 mg/L. (Table 1) To evaluate the role of the SOS response in the emergence of resistant mutants, selected strains were exposed to different selective concentrations of ciprofloxacin above the MIC (see Table 1 ). At a fixed concentration of 1 mg/L ciprofloxacin, no mutants were obtained for the ATCC and EC02 groups. The EC04 WT strain displayed a mutation rate of 2%10
#5
, and strains with modified SOS response (LexA1/DrecA) showed a decrease in mutation rate of 10-fold and no mutants, respectively. At 2.5 mg/L ciprofloxacin, the EC04 group produced no mutants. The WT strain EC08 showed a mutation rate of 5%10
, which compared with undetectable levels of mutants in its isogenic RecA-deficient counterpart. Mutation rates for strains belonging to the EC09 group with modified SOS response (DrecA/LexA1) were 3%10 #6 and 4%10
#4
, respectively. At 4%MIC, inactivation of the SOS response (mediated by LexA1) produced a 10-to 100-fold decrease in mutation rate for ATCC, EC04 and EC09, although interestingly no mutants grew from RecA-deficient strains under these conditions in any group (Table 1) . EC59 data are not included due to its high level of resistance.
These results indicate that suppression of the SOS response hampers acquired ciprofloxacin resistance in LLQR E. coli and has a major effect on DrecA mutants (SOS inactivation) compared with LexA1 mutants (SOS hypoactivation).
Suppression of SOS response reduces MPCs of quinolone for LLQR E. coli
The ATCC, EC02, EC04 and EC08 groups carrying modifications in the SOS response (recA deletion or LexA1) were used to study MPC parameters. Ciprofloxacin MICs ranged between 0.004 and 2 mg/L, from WT highly susceptible to intermediately susceptible (according to CLSI guidelines 22 ). The ciprofloxacin MPC values for all isogenic strains with recA deletion or LexA1 were 8-and 2-fold lower, respectively, than for the WT strain (Table 1 ). An 8-fold decrease for EC02 and EC04 (recA deletion strains) relative to WT reduced MPC values of ciprofloxacin to 0.5 and 1 mg/L, respectively. These concentrations are below the maximum serum concentrations (2.5 mg/L).
Although the mutant selection window (MSW) was wider for WT E. coli ATCC 25922 (256) than for the strains with modifications in the gyrA and parC genes (16-64), absolute MPC values in these 
Suppression of SOS response delays spatiotemporal microbial evolution
Using the agar gradient plate experiments, we demonstrated a notable delay in the spatiotemporal evolution of quinolone resistance in accordance with the SOS response (recA deletion) in isogenic LLQR (EC02, EC04, EC08) E. coli strains harbouring several molecular resistance mechanisms ( Figure S1 ). Although multiple lineages evolved towards resistance in both WT strains and those with a deficient SOS response, the number of lineages and the progression towards higher levels of resistance was much more evident in the presence of a functional SOS response. This is especially relevant in LLQR phenotypes at clinically relevant concentrations of quinolones ( Figure S1C and D) . Regardless of SOS response functionality, adjacent mutant lineages exclude each other and compete for limited space, resulting in some lineages completely blocking the growth of others ( Figure S1 ). The twenty-nine evolved mutants obtained in these assays were subjected to whole-genome sequencing. No differences (associated with type of quinolone resistance mutation) were found depending on the functionality of the SOS response. No new modifications of the topoisomerase genes were identified. Some of these mutants showed modifications in the redox-sensitive transcription activator, SoxR (G121D), DNA repair proteins such as RecQ (V536L!A539S) or UvrD (R421P), the cell division protein, FtsA (E203G), and the regulator of outer membrane proteins, EnvZ (P248Q).
Suppression of SOS response modifies bacterial fitness in LLQR E. coli
The six mutants harbouring recA deletions were tested against their respective WTs in growth competition assays to measure the fitness costs associated with the resistance mutations carried and suppression of the SOS response. For every pair of strains tested, recA deletion produced alterations in fitness, which varied in magnitude depending on the presence/absence of the antibiotic, and there was no correlation between fitness and the level of quinolone resistance (Figure 1a ). In the absence of ciprofloxacin, there was a decreased fitness of 19%-28% relative to the WT, with the greatest decrease in the EC59 strain. In the presence of DNAdamaging antibiotics, two concentrations of ciprofloxacin were studied. At 0.5%MIC of ciprofloxacin (the MIC value refers to the RecA-deficient strain), there was a bigger drop in fitness (by 33%-50%) than in the non-induced group, with the greatest loss of fitness being for EC09 (Figure 1b) . The ATCC, EC02 and EC04 groups were selected for treatment with a fixed concentration of ciprofloxacin of 0.002 mg/L (equivalent to the concentration of ciprofloxacin found in environmental wastewater 29 ) and showed decreased fitness of 81%, 30% and 28%, respectively (Figure 1c) .
Suppression of SOS response increases in vitro PAE in both WT and LLQR E. coli
In vitro PAE was determined to evaluate the impact of suppression of the SOS response after exposure to fixed ciprofloxacin concentrations (1 mg/L, i.e. the CLSI breakpoint for resistance, 22 and 2.5 mg/L, i.e. the C max of ciprofloxacin 23 ), as well as the time needed for recovery after antimicrobial stress. After 2 h exposure, the in vitro PAE of ciprofloxacin at 1 and 2.5 mg/L was .6 h against recA-deficient E. coli ATCC 25922 compared with 2 h against WT E. coli ATCC 25922 (Figure 2) . Likewise, for the LLQR phenotypes EC02, EC04 and EC08, at these clinically significant concentrations of ciprofloxacin, the PAE was observed to be 3 h longer in the isogenic strains with the deficient SOS response (Figure 2 ). Figure 3 shows the relative biofilm production in M9 minimal medium at sub-MIC concentrations of ciprofloxacin (1/16%MIC relative to the MIC of SOS WT). A reduction of 22%-80% was observed when recA was deleted. Absorbance values were 0.546-0.438 for the WT strains, whereas those for their isogenic recA-deficient counterparts were 0.410-0.105 (threshold value indicative of biofilm production: 0.08). LexA1 mutants had a minor effect on biofilm formation compared with recA deletion under the same conditions.
Effect of suppression of SOS response on biofilm formation under subinhibitory concentrations
Discussion
The SOS response plays an important role in adaptation and acquired bacterial resistance to antibiotics, and has been proposed as an attractive target for increasing bacterial susceptibility to antibiotics and combating the emergence of resistance. [17] [18] [19] 32 Lowlevel resistance phenotypes, such as LLQR (which can be exposed to sub-lethal levels of antibiotics during antimicrobial treatment), pose a significant threat of the development of clinical resistance. 18, 19, 32 Apart from the effect that the suppression of the SOS response has in enhancing the bactericidal activity of antimicrobial agents such as quinolones, significant questions remain unanswered about the possible impact of SOS response suppression as an evolutionary strategy for reversing and tackling the evolution of antibiotic resistance. 17, 18 In this study, we determined the efficacy of SOS response suppression as a strategy for disrupting the spatiotemporal evolution of resistance and other important clinical parameters such as bacterial fitness, biofilm formation and PAE under therapeutic concentrations using an isogenic collection with an altered SOS response (Table S1 14 ) in combination with chromosomal and PMQR mechanisms (including susceptible, LLQR and resistant phenotypes).
Our study showed that targeting the SOS pathways in LLQR phenotypes at clinically significant concentrations slowed down mutagenesis and blocked the acquisition of resistance (Table 1 and Figure S1 ). For RecA-deficient strains, a huge drop in the mutation rate was observed in those harbouring mechanisms of quinolone resistance (ranging from susceptible, intermediate Blocking quinolone resistance by suppressing the SOS response JAC susceptible to low-level resistant) at 4%MIC of ciprofloxacin, from which it was concluded that suppression of the SOS response mediated by recA deletion interferes with the ability of bacteria to evolve to higher resistance levels independently of the quinolone resistance phenotype. This behaviour was similar at clinically relevant concentrations of ciprofloxacin for LLQR phenotypes, supporting the ability of this strategy to tackle the emergence of resistance. For the EC08 group, at ciprofloxacin C max (2.5 mg/L), suppression of the SOS response reduced the mutation rate .10 3 -fold, preventing the emergence of mutations. These results correlated well with a recently published in vivo murine model, in which the EC08 group was used to show that suppression of the SOS response increased the in vivo efficacy of ciprofloxacin.
14 On the other hand, a hypoactive SOS response based on LexA1 resulted in a minor reduction of the mutation rate relative to recA-deleted strains. Furthermore, we showed that suppression of the SOS response based on recA deletion reduced quinolone MPC values in LLQR E. coli (groups EC02 and EC04, Table 1 ) below the maximum serum concentration of ciprofloxacin (2.5 mg/L 23 ). Hence, suppression of the SOS response reverses the effects of low-level quinolone resistance mechanisms, such as S83L and S80R on GyrA and ParC, on the MPC value and the emergence of mutants. 20, 33 RecA and LexA have been proposed as therapeutic targets that interfere with SOS induction. 15, 16, [34] [35] [36] [37] Our results suggest that the effects of SOS response suppression (DrecA and LexA1) largely mimic each other in terms of synergy and acquired resistance, even in low-level resistance phenotypes, although a greater degree of susceptibility and control of emergence of resistance can be observed with the DrecA strain. 13, 14 Our data suggest that targeting either RecA or LexA could be of interest, although it is worth noting that each probably presents its own challenges. RecA, unlike LexA, has important human homologues (i.e. the Rad51 family), which makes specificity a particularly important requirement for targeting RecA; indeed, some high-throughput screening efforts have yielded compounds that selectively target RecA or Rad51. 13, 33 Furthermore, recA deletion has an impact other than leading to suppression of the SOS response, since it has additional implications for important processes such as homologous Figure 1 . Bacterial fitness in in vitro competition assays for ATCC, EC02, EC04, EC08, EC09 and EC59 recA mutants compared with WT strains studied in the absence of ciprofloxacin (a), at 0.5%MIC for the recA mutant (b), and with 0.002 mg/L of ciprofloxacin (c). 29 Competition index values from each independent experiment are plotted. The broken horizontal line indicates a competition index value of 1, and means are indicated by short continuous horizontal lines. Significant P values compared with the respective WT for SOS response are noted: *P , 0.001. Blocking quinolone resistance by suppressing the SOS response JAC recombination. 38 It is unknown if the SOS response suppression could interfere positively or negatively with the impact of other relevant processes involved in genetic variability such as the DNA mismatch repair system. 39 A key aspect of bacterial survival is the ability to evolve while migrating across spatially varying environmental challenges. The gradient plate assays enabled us to study microbial adaptation and to visualize directly the evolutionary dynamics of each group of strains (WT versus DrecA strains). Suppression of the SOS response showed a reduction in the number of lineages observed relative to each WT strain after the same period of time, which supports our previous results in terms of mutation rate and MPC data ( Table 1 and Figure S1 ) and provides new evidence of the effectiveness of this strategy in tackling the evolution of resistance. 3, 17, 26 WGS was performed for selected mutants. Unexpectedly, only a few modifications were found: in the redox-sensitive transcription activator SoxR, in DNA repair proteins (RecQ or UvrD), in the cell division protein FtsA, and in the regulator of outer membrane proteins EnvZ.
Using competition assays, we noted a remarkable fitness cost associated with recA deletion in the absence of external DNAdamaging agents such as antimicrobials in LLQR phenotypes. This effect was even higher when competition assays were performed in the presence of sub-MIC concentrations of ciprofloxacin (simulating sub-therapeutic or environmental concentrations of fluoroquinolones) 29 ( Figure 1 ). In this connection, it is well known that the SOS response also induces increases in three DNA polymerases (pol II, pol IV, pol V), conferring a competitive fitness advantage during the stationary phase of the bacterial lifecycle. 40 Hence, the absence of RecA could explain the fitness cost observed in both WT and LLQR E. coli phenotypes.
Other important parameters reported in this study, such as in vitro PAE (prolonged by 3 h in RecA-deficient strains, including LLQR and resistant strains) and biofilm formation (reduced in RecA-deficient strains at sub-MIC concentrations) showed additional beneficial properties of this possible therapeutic strategy (Figures 2 and 3) . Suppression of the SOS response would help prolong the PAE after withdrawing the antimicrobial, which is potentially advantageous in therapy. Bacterial adherence is a key step in bacterial physiology and pathogenesis. The SOS response has been shown to be involved in the adherence of E. coli to surfaces. [41] [42] [43] Studies have shown that biofilm formation depends on the ability of the bacteria to induce the SOS response. 7 In conclusion, this study shows that suppression of the SOS response is an interesting strategy for reversing and tackling the evolution of antibiotic resistance in a set of E. coli phenotypes ranging from highly susceptible to highly quinolone resistant, and plays a significant role in other important clinical parameters such as bacterial fitness, biofilm formation and PAEs under therapeutic concentrations. The development of RecA inhibitors could function as an adjuvant therapy, leading to reversion of drug resistance.
